 COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT Announced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government grant of approximately 17 million to evaluate the program for post-COVID pulmonary fibrosis Signed respiratory and ophthalmology agreement with Genentech with a 20 million upfront payment and more than 1.4 billion in potential additional milestone payments Tim Demuth, M.D., Ph.D., appointed Chief Medical Officer and Shane Olwill, Ph.D. 